Vestronidase alfa is indicated for the treatment of non-neurological manifestations of MPS VII.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||09/04/2017|
|Rapid review completed||22/05/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vestronidase alfa compared with the current standard of care.|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.